Table 3.
Median postpartum laboratory values among women continuing or stopping antiretroviral therapy postpartum according to therapy during pregnancy.
| All women | ZDV monotherapy | Combination therapy | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Parameter | +/- | +/+ | P | +/- | +/+ | p | +/- | +/+ | P |
| CD4+ lymphocyte count | 733.2 | 701.7 | .47 | 725.2 | 711.0 | .84 | 754 | 690.5 | .33 |
| CD4+ lymphocyte % | 34.8 | 33.9 | .42 | 34.2 | 32.6 | .31 | 36.3 | 34.9 | .44 |
| CD8+ lymphocyte count | 935.1 | 949.9 | .81 | 985.3 | 1042.8 | .56 | 818.4 | 874.0 | .48 |
| CD8+ lymphocyte % | 44.7 | 44.7 | .98 | 46.4 | 48.1 | .41 | 40.8 | 41.9 | .67 |
| CD19+ % | 9.0 | 9.6 | .72 | 9.6 | 8.9 | .72 | |||
| CD8+CD57+ % | 17.3 | 16.6 | .80 | 18.8 | 18.8 | .99 | |||
| CD8+DR+ % | 36.3 | 26.6 | .02 | 35.9 | 24.9 | .01 | |||
| CD16+CD56+ % | 4.8 | 7.4 | .04 | 5.2 | 7.8 | .12 | |||
| CD8+CD38+ % | 47.6 | 36.7 | .001 | 49.8 | 40.5 | .04 | |||
| High sensitivity C-reactive protein (mg/L) | 2.8 | 3.0 | .69 | 2.7 | 3.1 | .58 | |||
| Cholesterol (mg/dL) | 177.7 | 188.7 | .10 | 177.7 | 188.7 | .11 | |||
| High density lipoprotein (mg/dL) | 47.8 | 49.3 | .56 | 48.1 | 49.2 | .67 | |||
| Low density lipoprotein (mg/dL) | 95.6 | 101.5 | .30 | 94.6 | 100.5 | .35 | |||
| Triglycerides (mg/dL) | 180.0 | 184.7 | .81 | 181.0 | 187.1 | .77 | |||
| Leptin (ng/dL) | 21.0 | 19.3 | .54 | 20.1 | 19.7 | .90 | |||
| Interleukin-6 (pg/dL) | 1.9 | 1.6 | .22 | 2.2 | 1.7 | .33 | 1.7 | 1.6 | .65 |
| Lipoprotein phospholipase A-2 (ng/dL) | 166.1 | 187.0 | .05 | 170.6 | 188.5 | .37 | 161.3 | 185.5 | .05 |
+/- indicates women who stopped therapy at delivery; +/+ indicates women who continued therapy after delivery. Postpartum specimens were collected at six to 12 months postpartum.